Zostavax Sales Data
Last updated: May 2013 (updated quarterly).
The following data shows Zostavax U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2012 | 70 ( 14) |
$222,633 | 14.39% | 223 | 10.95% |
| Q3 2012 | 84 ( ) |
$194,633 |  |
201 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| October 5, 2011 | Health Tip: Getting the Shingles Vaccine |
| March 24, 2011 | U.S. Shingles Vaccine Approval Expanded |
| January 12, 2011 | Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease |
| January 12, 2011 | Vaccine For Shingles Ailment Effective -- And Seldom Used, Study Says |
| January 11, 2011 | Shingles Vaccine Looks Like a Safe Bet for Seniors: Study |
| May 14, 2010 | New Large Study Results Confirm Safety Profile of Zostavax, Merck's Shingles Vaccine, in People Aged 60 or Older |
| February 8, 2010 | Getting Shingles Vaccine Easier |
